SOMNOMED LIMITED (SOM)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

SOM - SOMNOMED LIMITED

FNArena Sector : Medical Equipment & Devices
Year End: June
GICS Industry Group : Health Care Equipment & Services
Index:

LAST PRICE CHANGE +/- CHANGE % VOLUME

$1.63

04 Oct
2022

0.070

OPEN

$1.62

4.49%

HIGH

$1.72

13,228

LOW

$1.62

TARGET
$1.88 15.3% upside
OTHER COMPANIES IN THE SAME SECTOR
ELX . PGC . AHZ . COH . FPH . IPD . LHC . NAN . RMD . HLA . MX1 . CAT . VHT . ONE . IDX . PME . CSX . 4DX . BRN . EMV . UBI . LDX . RAP . RVA . MEB . IME . PCK . CMP . CYC . IMR . VTI . OVN . EYE . CGS . CU6 . TRJ . EBR . PEB . AT1 . CBL .
FNARENA'S MARKET CONSENSUS FORECASTS
SOM: 1
Title FY21
Actual
FY22
Actual
FY23
Forecast
FY24
Forecast
EPS (cps) xxx - 5.7 - 0.0 xxx
DPS (cps) xxx 0.0 0.0 xxx
EPS Growth xxx N/A N/A xxx
DPS Growth xxx N/A N/A xxx
PE Ratio xxx N/A N/A xxx
Dividend Yield xxx N/A 0.0% xxx
Div Pay Ratio(%) xxx N/A N/A xxx

Dividend yield today if purchased 3 years ago: 0.00%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

0.00

Estimated Dividend Growth
(Average Of Past Three Years)

 %

Amount Invested

Tell Me The Dividend After This Many Years

Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2022 FactSet UK Limited. All rights reserved
Title 201720182019202020212022
EPS Basic xxxxxxxxxxxxxxx-5.7
DPS All xxxxxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxxxxx72.6 M
Book Value Per Share xxxxxxxxxxxxxxx33.6
Net Operating Cash Flow xxxxxxxxxxxxxxx1.9 M
Net Profit Margin xxxxxxxxxxxxxxx-6.10 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201720182019202020212022
Return on Capital Employed xxxxxxxxxxxxxxx-14.77 %
Return on Invested Capital xxxxxxxxxxxxxxx-12.25 %
Return on Assets xxxxxxxxxxxxxxx-7.75 %
Return on Equity xxxxxxxxxxxxxxx-14.77 %
Return on Total Capital xxxxxxxxxxxxxxx-10.22 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx0.8 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

This is work in progress. Bear with us. It'll be amazing.

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

1.0

No. Of Recommendations

1
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Morgans

24/08/2022

1

Add

$1.88

15.34%

There were no significant surprises for Morgans from SomnoMed's FY22 earnings report with sales up 16%, in line with expectations and EBITDA margins at a "solid" 70%.

SomnoMed is on track for the global launch of Rest Assure in FY23 and the strategy of investing for growth at the expense of underlying profitability remains in tack according to Morgans.

The uncertainty around the success of Rest Assure remains, but success would extend SomnoMed's leading market position and potentially an issue for CPAP operators, making the company a takeover target in the future, suggests the broker.

An Add rating is maintained and the price target is lowered to $1.88 from $1.91.

FORECAST
Morgans forecasts a full year FY23 dividend of 0.00 cents and EPS of minus -0.01 cents.
Morgans forecasts a full year FY24 dividend of 0.00 cents and EPS of 0.01 cents.

SOM STOCK CHART